tiprankstipranks
Trending News
More News >
MiMedx Group (MDXG)
NASDAQ:MDXG
US Market
Advertisement

MiMedx Group (MDXG) AI Stock Analysis

Compare
485 Followers

Top Page

MDXG

MiMedx Group

(NASDAQ:MDXG)

Rating:79Outperform
Price Target:
$8.50
▲(16.28% Upside)
MiMedx Group's strong financial performance and positive earnings call sentiment are the primary drivers of the stock's score. The company's robust revenue growth and improved profitability, coupled with strategic guidance and product development, outweigh the high valuation concerns. Technical indicators support short-term momentum, although long-term resistance remains a consideration.
Positive Factors
Market Position
MDXG continues to grow versus difficult prior-year comparisons, a testament to the company's execution.
Product Sales
MDXG put up another quarter of strong product sales, with $93mn of revenue versus $89.4mn Street, or 7% growth versus 3% expectation.
Strategic Initiatives
Management remains optimistic about current strategic initiatives, with the recent launch of HELIOGEN expected to contribute meaningfully.
Negative Factors
Market Challenges
Potential $1.0-1.5bn in Medicare Skin Sub payments still up for grabs.
Reimbursement Uncertainty
Continuing reimbursement uncertainty disrupted the business in the physician office setting.

MiMedx Group (MDXG) vs. SPDR S&P 500 ETF (SPY)

MiMedx Group Business Overview & Revenue Model

Company DescriptionMiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
How the Company Makes MoneyMiMedx generates revenue primarily through the sale of its regenerative medicine products, which are marketed to hospitals, outpatient surgical centers, and clinics. Key revenue streams consist of direct sales of allograft tissue products used in wound care and surgical procedures. The company benefits from strategic partnerships with healthcare providers and distributors that help expand its market reach. Additionally, MiMedx may receive reimbursements from insurance companies for its products, further contributing to its earnings. The company's focus on innovation and clinical evidence supporting the efficacy of its products also plays a significant role in driving sales and attracting new customers.

MiMedx Group Earnings Call Summary

Earnings Call Date:Jul 30, 2025
(Q2-2025)
|
% Change Since: 12.12%|
Next Earnings Date:Oct 29, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive outlook due to record revenue and EBITDA, strong segment growth, and strategic product developments. However, there are challenges posed by anticipated changes in Medicare reimbursement and slower than expected clinical trial enrollments.
Q2-2025 Updates
Positive Updates
Record Quarterly Revenue and EBITDA
MiMedx achieved a record quarterly revenue of $99 million, marking a 13% year-over-year growth. The company also reported the highest adjusted EBITDA in its history at $24 million, which is 25% of net sales.
Strong Growth Across Key Segments
Both the Wound and Surgical franchises reported double-digit growth, with the Surgical segment growing by 15% and contributions across the portfolio, including increased sales of HELIOGEN.
Increased Full-Year Revenue Guidance
Due to strong year-to-date performance, MiMedx raised its full-year revenue growth outlook from the high single digits to the low double digits. The full-year adjusted EBITDA margin is expected to be above 20%.
Strategic Product Development and Partnerships
The company is advancing its product pipeline with new offerings like EPIXPRESS and collaborative efforts such as the co-marketing of Vaporox Inc.'s VHT device, enhancing its wound care solutions.
Negative Updates
Potential Market Impact Due to Medicare Reimbursement Changes
The introduction of a fixed payment for skin substitutes by CMS at $125.38 per square centimeter could impact the market significantly. MiMedx anticipates some market share shifts and price adjustments, with uncertainty about the exact market size post-reform.
Delays in Clinical Trials
Enrollment in the randomized controlled trial for EPIEFFECT is slower than anticipated, potentially delaying crucial readouts needed for regulatory and market competitiveness.
Company Guidance
During the MiMedx Second Quarter 2025 Conference Call, the company announced robust financial performance and raised guidance for the remainder of the year. Notably, net sales grew by 13% year-over-year to $99 million, marking the highest quarterly revenue in the company's history. The adjusted gross profit margin stood at 84%, while adjusted EBITDA reached $24 million, or 25% of net sales. MiMedx ended the quarter with $119 million in cash, reflecting a $12 million increase. Both the Wound and Surgical franchises achieved double-digit growth, with the Surgical business expanding by 15%. The company anticipates further growth, revising its full-year revenue growth outlook from high single digits to low double digits and projecting a full-year adjusted EBITDA margin above 20%. Additionally, MiMedx is preparing for upcoming Medicare reimbursement reforms slated for January 2026, which could impact the market dynamics but are expected to favor the company's competitive positioning due to its robust evidence supporting product efficacy.

MiMedx Group Financial Statement Overview

Summary
MiMedx Group has shown strong revenue growth and profitability improvements, with a robust gross profit margin of 81.9% and a positive net profit margin of 11.4% for TTM 2025. The solid balance sheet with low leverage and strong cash flow generation underscores financial stability.
Income Statement
82
Very Positive
MiMedx Group has shown strong growth in revenue over the observed periods, with a notable increase from $267.8M in 2022 to $352.4M in TTM (Trailing-Twelve-Months) 2025. Gross profit margin is robust at 81.9% for TTM, indicating efficient cost management. The net profit margin has turned positive, reaching 11.4% in TTM 2025 from negative figures in previous years, signaling improved profitability. However, the decline in EBIT from 2024 to TTM 2025 suggests some operational cost challenges.
Balance Sheet
76
Positive
The company's balance sheet reflects a solid equity position with an equity ratio of 74.98% in TTM 2025, indicating a strong capital structure. The debt-to-equity ratio is very low at 0.01, showcasing minimal leverage, which reduces financial risk. Return on equity is positive at 19.81%, reflecting efficient use of equity to generate profits. Nonetheless, the high level of cash reserves relative to debt suggests missed opportunities for investment or growth.
Cash Flow
88
Very Positive
MiMedx Group demonstrates strong cash flow generation with free cash flow growing significantly, highlighted by a free cash flow of $68.7M in TTM 2025. The operating cash flow to net income ratio is favorable, indicating efficient cash generation from operations. Furthermore, the free cash flow to net income ratio of 1.71 signifies robust cash conversion efficiency. Overall, the cash flow position is solid, underpinning financial stability and flexibility.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue352.38M348.88M321.48M267.84M258.62M248.23M
Gross Profit288.54M288.81M266.84M219.53M215.33M208.90M
EBITDA54.95M64.34M40.52M-10.69M-1.89M-45.76M
Net Income40.18M42.42M67.44M-30.20M-10.29M-49.28M
Balance Sheet
Total Assets270.42M263.92M239.05M171.43M187.93M202.03M
Cash, Cash Equivalents and Short-Term Investments106.43M104.42M82.00M65.95M87.08M95.81M
Total Debt18.66M24.84M48.10M48.59M48.13M47.70M
Total Liabilities67.64M70.81M96.33M189.42M187.85M202.18M
Stockholders Equity202.78M193.11M142.72M-17.99M82.00K-150.00K
Cash Flow
Free Cash Flow68.32M64.52M24.79M-20.58M-5.45M-34.82M
Operating Cash Flow67.55M66.20M26.77M-17.89M-1.98M-30.26M
Investing Cash Flow-3.96M-9.58M-2.15M-2.66M-3.40M-4.55M
Financing Cash Flow-3.61M-34.20M-8.57M-580.00K-3.35M61.56M

MiMedx Group Technical Analysis

Technical Analysis Sentiment
Positive
Last Price7.31
Price Trends
50DMA
6.65
Positive
100DMA
6.73
Positive
200DMA
7.67
Negative
Market Momentum
MACD
0.13
Positive
RSI
59.42
Neutral
STOCH
47.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDXG, the sentiment is Positive. The current price of 7.31 is above the 20-day moving average (MA) of 7.08, above the 50-day MA of 6.65, and below the 200-day MA of 7.67, indicating a neutral trend. The MACD of 0.13 indicates Positive momentum. The RSI at 59.42 is Neutral, neither overbought nor oversold. The STOCH value of 47.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MDXG.

MiMedx Group Risk Analysis

MiMedx Group disclosed 40 risk factors in its most recent earnings report. MiMedx Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

MiMedx Group Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$1.08B33.8916.62%6.85%-67.67%
60
Neutral
HK$19.40B4.63-1.43%3.30%11.28%-16.47%
59
Neutral
$1.47B-39.36%83.88%15.24%
56
Neutral
$2.14B-63.41%-7.26%-15.33%
54
Neutral
$973.39M-53.16%636.99%27.10%
52
Neutral
$2.31B-363.16%30.20%-7.22%
47
Neutral
$1.49B-27.17%-30.25%-9.70%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MDXG
MiMedx Group
7.31
0.59
8.78%
CLDX
Celldex
22.46
-15.24
-40.42%
IOVA
Iovance Biotherapeutics
2.69
-9.21
-77.39%
ARDX
Ardelyx
6.11
-0.20
-3.17%
OCUL
Ocular Therapeutix
12.30
3.29
36.51%
LQDA
Liquidia Technologies
26.84
17.01
173.04%

MiMedx Group Corporate Events

Business Operations and StrategyFinancial Disclosures
MiMedx Group Reports Record Q2 2025 Financial Results
Positive
Jul 30, 2025

MiMedx Group announced record financial results for the second quarter of 2025, with net sales reaching $99 million, a 13% increase from the previous year. The company achieved its highest quarterly net sales, driven by growth in its Wound and Surgical franchises, and reported a net income of $10 million. MiMedx also raised its net sales growth expectations for 2025, anticipating low double-digit growth. The company is engaging with CMS on proposed reimbursement reforms for skin substitutes, which could impact future operations and market positioning.

Shareholder Meetings
MiMedx Group Holds Annual Shareholder Meeting
Neutral
Jun 20, 2025

On June 18, 2025, MiMedx Group held its Annual Meeting of Shareholders, where 85.7% of the voting shares were represented. During the meeting, nine directors were re-elected, an advisory resolution on executive compensation was approved, Deloitte & Touche LLP was ratified as the independent auditor for 2025, an amendment to the 2016 Equity and Cash Incentive Plan was approved, and it was decided that the advisory vote on executive compensation would occur annually.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 23, 2025